美贝维林促进原位膀胱替代术后早期控尿的随机试验
这项随机试验纳入原位膀胱替代术后第一年内尿失禁的成年男性患者,比较美贝维林135 mg每日三次用3个月与安慰剂的疗效。主要结局为膀胱癌指数尿域评分和卫生护垫使用。结果显示美贝维林组3个月尿域评分显著更高(83.27±12.21 vs 67.79±13.05,p<0.001),护垫使用减少比例更高(36.5% vs 63.8%,p=0.007)。
要点
- 美贝维林135 mg每日三次用3个月可改善原位膀胱替代术后尿域评分。
- 美贝维林组3个月护垫使用减少比例高于安慰剂组(36.5% vs 63.8%)。
- 两组不良事件(便秘、腹胀)无显著差异(p=0.25)。
核心结论
- 美贝维林可加速男性回肠原位膀胱替代术后第一年内的控尿恢复。
研究设计与样本
- 随机试验纳入原位膀胱替代术后第一年内尿失禁的成年男性患者,美贝维林135 mg或安慰剂每日三次用3个月。
- 安慰剂组47例、美贝维林组52例完成随访。
主要发现
- 3个月时膀胱癌指数尿域评分均值±SD在安慰剂组为67.79±13.05、美贝维林组为83.27±12.21(p<0.001)。
- 3个月时护垫使用减少患者数在安慰剂组为30例(63.8%)、美贝维林组为19例(36.5%)(p=0.007)。
- 便秘发生率安慰剂组1例(2.1%)、美贝维林组3例(5.8%);腹胀仅美贝维林组2例(3.8%)(p=0.25)。
临床怎么用
- 对于原位膀胱替代术后第一年内尿失禁的男性患者,可考虑短期使用美贝维林以促进控尿恢复。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the effect of mebeverine in the enhancement of the orthotopic bladder substitute continence. MATERIALS AND METHODS: A randomized trial was carried out for incontinent adult male patients during the first year post-orthotopic bladder substitute surgery. Patients were allocated to receive mebeverine 135 mg or placebo 3 times a day for only 3 months. The primary outcome was to compare the continence improvement between groups, assessed by the urinary domain of the Bladder Cancer Index and sanitary pad use. The secondary outcomes were to assess the safety of the drugs used. RESULTS: In placebo group 47 and in mebeverine group 52 patients completed followup. The median (range) interval time between orthotopic bladder substitute surgery and starting treatment was 7 (3-10) months and 6.5 (3-10) months in the placebo and mebeverine group, respectively (p=0.3). Compared to the baseline evaluation, the 3-month urinary domain of Bladder Cancer Index scores improved in both groups with significant improvement in the mebeverine group. The mean±SD 3-month urinary domain of Bladder Cancer Index was 67.79±13.05 and 83.27±12.21 in the placebo and mebeverine group, respectively (p <0.001). Also, the 3-month patient pad use decreased to 30 (63.8%) and 19 (36.5%) patients in the placebo and mebeverine group, respectively (p=0.007). Constipation occurred in 1 (2.1%) and 3 (5.8%) patients in the placebo and mebeverine group, respectively; abdominal distention occurred in 2 (3.8%) in the mebeverine group (p=0.25). CONCLUSIONS: Mebeverine accelerated continence development in male patients with ileal orthotopic bladder substitute during the first year post-orthotopic bladder substitute construction.
引用
- Hashem A, Abol-Enein H, Laymon M, et al. A Randomized Trial to Examine the Utility of Mebeverine on the Early Return of Continence Following Orthotopic Bladder Substitution. J Urol. 2020. PMID: 33350325. doi:10.1097/JU.0000000000001526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。